The value of comparative efficacy studies in informing rheumatology guidelines
Nature Reviews Rheumatology, Published online: 21 September 2022; doi:10.1038/s41584-022-00846-9New research reinforces the fact that most recommendations in rheumatology are not informed by comparative efficacy randomized controlled trials. Performing these studies is time and resource intensive. Policies and funding to perform these studies in a timely and resource constraint manner are essential. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 21, 2022 Category: Rheumatology Authors: Raveendhara R. Bannuru Source Type: research
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?
Nature Reviews Rheumatology, Published online: 16 September 2022; doi:10.1038/s41584-022-00843-yNew research shows that TNF can directly induce osteoclastogenesis from transforming growth factor-β (TGFβ)-primed macrophages and that knockout of TGFβ signalling limits TNF-induced arthritic bone erosion in mice, suggesting that TGFβ inhibition could enhance the effect of anti-TNF therapy in rheumatoid arthritis. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 16, 2022 Category: Rheumatology Authors: Zhenqiang Yao Brendan F. Boyce Source Type: research
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management
Nature Reviews Rheumatology, Published online: 15 September 2022; doi:10.1038/s41584-022-00819-yIn this Review, the authors summarize the genetic factors associated with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). They describe the findings from genetic association studies, their pathogenic significance and their implications for the classification, management and prognosis of AAV. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 15, 2022 Category: Rheumatology Authors: Giorgio Trivioli Ana Marquez Davide Martorana Michelangelo Tesi Andreas Kronbichler Paul A. Lyons Augusto Vaglio Source Type: research
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis
Nature Reviews Rheumatology, Published online: 15 September 2022; doi:10.1038/s41584-022-00833-0In this Review, the authors discuss the roles of sex and gender in relation to axial spondyloarthritis. Although evidence now suggests that the disease has equal prevalence in men and women, important differences occur in phenotypes, response to therapy and outcomes. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 15, 2022 Category: Rheumatology Authors: Rachael Stovall Irene E. van der Horst-Bruinsma Shao-Hsien Liu Tamara Rusman Lianne S. Gensler Source Type: research
Emerging concepts of type I interferons in SLE pathogenesis and therapy
Nature Reviews Rheumatology, Published online: 12 September 2022; doi:10.1038/s41584-022-00826-zIn this Review, Psarras, Wittmann and Vital discuss evidence of the production of type I interferons by cells and tissues other than haematopoietic cells. These interferons can have local effects, and their roles in the pathogenesis of systemic lupus erythematosus suggest the value of interferon-blocking therapies for treatment of this condition. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 12, 2022 Category: Rheumatology Authors: Antonios Psarras Miriam Wittmann Edward M. Vital Source Type: research
Transitional care: time for a rethink?
Nature Reviews Rheumatology, Published online: 12 September 2022; doi:10.1038/s41584-022-00836-xTransitional care in rheumatology has been debated for over three decades and yet unmet needs of young people are still being reported. Why the slow progress? Perhaps we need to stop talking about transitional care in rheumatology and talk more about developmentally appropriate health care for young people with rheumatic conditions. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 12, 2022 Category: Rheumatology Authors: Janet E. McDonagh Albert Farre Source Type: research
New screening tool developed to aid diagnosis of axial PsA
Nature Reviews Rheumatology, Published online: 08 September 2022; doi:10.1038/s41584-022-00840-1A short questionnaire designed for use by dermatologists to screen patients with psoriasis can be used for the selection of individuals for MRI assessment of axial psoriatic arthritis. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 8, 2022 Category: Rheumatology Authors: Robert Phillips Source Type: research
Non-canonical protective role for histone demethylase in arthritis
Nature Reviews Rheumatology, Published online: 07 September 2022; doi:10.1038/s41584-022-00837-wA new study reveals a non-canonical function for the histone demethylase JMJD1C that restrains plasma cell differentiation and protects mice from experimental arthritis. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 7, 2022 Category: Rheumatology Authors: Jessica McHugh Source Type: research
Novel JAK3-specific inhibitor safe and effective in mouse RA model
Nature Reviews Rheumatology, Published online: 07 September 2022; doi:10.1038/s41584-022-00839-8The newly developed Z583 is a potent and highly specific inhibitor of JAK3, with a favourable in vitro and in vivo safety profile and effectiveness in treatment of collagen-induced arthritis in mice. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 7, 2022 Category: Rheumatology Authors: Robert Phillips Source Type: research
Targeting the IVD clock to halt degeneration
Nature Reviews Rheumatology, Published online: 07 September 2022; doi:10.1038/s41584-022-00838-9New research sheds light on how disruption of peripheral circadian rhythms mediates inflammation-induced intervertebral disc degeneration and suggests a therapeutic approach to target these mechanisms. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 7, 2022 Category: Rheumatology Authors: Sarah Onuora Source Type: research
Global epidemiology of rheumatoid arthritis
Nature Reviews Rheumatology, Published online: 06 September 2022; doi:10.1038/s41584-022-00827-yIn this Review, the authors summarize and discuss regional differences in the prevalence and incidence of rheumatoid arthritis (RA), and describe temporal trends associated with the disease as well as evidence related to risk factors. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 6, 2022 Category: Rheumatology Authors: Axel Finckh Beno ît Gilbert Bridget Hodkinson Sang-Cheol Bae Ranjeny Thomas Kevin D. Deane Deshir é Alpizar-Rodriguez Kim Lauper Source Type: research
New evidence for the ‘cusp theory’ to explain HLA associations in SLE
Nature Reviews Rheumatology, Published online: 06 September 2022; doi:10.1038/s41584-022-00835-yNew findings support the existence of an antigen presentation-independent mechanism known as the ‘cusp theory’ and the involvement of a newly discovered ‘lupus epitope’ in systemic lupus erythematosus susceptibility. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - September 6, 2022 Category: Rheumatology Authors: Jessica McHugh Source Type: research
Kawasaki disease and MIS-C share a host immune response
Nature Reviews Rheumatology, Published online: 25 August 2022; doi:10.1038/s41584-022-00820-5Multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease are both hyperinflammatory disorders associated with infectious diseases, but are they distinct syndromes or do they exist along a continuum? A comparison of the host immune response in these illnesses provides surprising new insights. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - August 25, 2022 Category: Rheumatology Authors: Paul Tsoukas Rae S. M. Yeung Source Type: research
Sarcoidosis: can tofacitinib slay the dragon?
Nature Reviews Rheumatology, Published online: 23 August 2022; doi:10.1038/s41584-022-00832-1Lack of understanding of the immunology of sarcoidosis has limited therapeutic progress. However, evidence from a small open-label trial suggests that treatment with the Janus kinase inhibitor tofacitinib can improve sarcoidosis symptoms, predominantly by inhibiting type 1 immunity. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - August 23, 2022 Category: Rheumatology Authors: Nadera J. Sweiss Robert Baughman Source Type: research
Critical appraisal of serum urate targets in the management of gout
Nature Reviews Rheumatology, Published online: 16 August 2022; doi:10.1038/s41584-022-00816-1Gout can be effectively treated with long-term urate-lowering therapy. Current guidelines advocate the use of a treat-to-target serum urate strategy, with a target serum urate concentration of (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - August 16, 2022 Category: Rheumatology Authors: Lisa K. Stamp Nicola Dalbeth Source Type: research
